Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 4/20 | 0.33 |
| ▸ | SKP1 | P63208 | 4/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258990 | 0.92 | CYP11B2 (0.32) | CKS1BSKP1SKP2CYP11B2RET | |
| SCHEMBL21258691 | 0.86 | CKS1B (0.33) | CKS1BSKP1SKP2CYP11B2RET | |
| SCHEMBL21258952 | 0.85 | PTGIR (0.37) | CKS1BSKP1SKP2FGFR1FGFR2 | |
| SCHEMBL21258946 | 0.84 | CKS1B (0.33) | CKS1BSKP1SKP2CYP11B2 | |
| SCHEMBL21258939 | 0.82 | CKS1B (0.38) | CKS1BSKP1SKP2CYP11B2 | |
| SCHEMBL21258669 | 0.82 | AKT1 (0.33) | RET | |
| SCHEMBL21258967 | 0.81 | CKS1B (0.34) | CKS1BSKP1SKP2CYP11B2RET | |
| SCHEMBL21258995 | 0.79 | CKS1B (0.38) | CKS1BSKP1SKP2 | |
| SCHEMBL21258681 | 0.79 | CKS1B (0.34) | CKS1BSKP1SKP2CYP11B2 | |
| SCHEMBL22781926 | 0.79 | MEN1 (0.35) | CKS1BSKP1SKP2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |